Aug 09, 2019 / 08:30AM GMT
Sigurdur Oli Olafsson - Hikma Pharmaceuticals PLC - CEO & Executive Director
Welcome, and thank you for joining us today both in the room and on the webcast. I'm Siggi Olafsson, the CEO of Hikma. And I am going to give you a quick update on the strategic progress we have made in the company today. With me today is Khalid Nabilsi, the CFO. And he will then take over and run through the financial results of the first half and the outlook for the full year. Then we will, of course, open it up for Q&A.
So as you know, and see from the results, they are very good. I'm very happy with -- for the start we made in 2019. All our businesses are performing well. Group delivered over $1 billion in revenue, up 7% from last year demonstrating a very strong organic growth. Across the group, we really are delivering more from our marketed products, benefiting from the breadth and durability of our portfolios. At the same time, we are launching new products, making good progress with the pipeline development.
I'll now give a little bit of a strategic overview of all the 3 businesses. So the chart
Half Year 2019 Hikma Pharmaceuticals PLC Earnings Call Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers